PCSK9 inhibitor reduced major CVD events in adults with no prior heart attack or stroke

via PCSK9 inhibitor reduced major CVD events in adults with no prior heart attack or strokeResearch Highlights: Results from the international VESALIUS-CV (TIMI 66) clinical trial found that among adults with atherosclerotic cardiovascular disease (ASCVD) or diabetes and no history of a prior heart attack or stroke, the PCSK9 inhibitor...